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Early treatment with ACE inhibitors of even moderate heart failure is clinically beneficial, even though haemodynamic
measurements cannot adequately quantitate such improvement. Neurohumoral assessment is, however, supposed to be more
accurate. In 55 patients with moderate heart failure (ejection fraction <, 35%), we investigated the dose-dependent effects of
ACE inhibition with quinapril taken orally (2-5, 5 or 10 mg b.Ld.) following a placebo-controlled, parallel design protocol
over 12 weeks. Plasma components of the renin angiotensin system, catecholamines and ANF were measured together with
haemodynamics both at rest and during exercise. Before ACE inhibitor treatment, median PRA, Ang I and II and cate-
cholamines were normal, while ANF was increased. All these parameters, including ACE activity, rose during exercise.
Chronic inhibition of ACE activity was dose-dependent and the maximal fall in Ang II occurred with quinapril 20
mg.day'1. Humoral changes appeared more assessible than haemodynamic alterations even though many of these changes
were reasonably correlated. The effects of chronic ACE inhibition on circulating neurohumoral components in patients with
moderate heart failure are small and dose-dependent. Since humoral changes are related to haemodynamics they should
account for the clinical benefit. Appropriately high doses of ACE inhibitors should be chosen for treatment of heart failure.
Introduction
The recently reported beneficial effect of early treatment
with angiotensin converting enzyme (ACE) inhibition in
asymptomatic patients with reduced left ventricular ejec-
tion fraction is an exciting step forward in the management
of congestive heart failure1'"31, and there is now little doubt
that ACE inhibitor treatment should be initiated very early
in the course of the disease. Nevertheless, several questions
remain to be addressed: there exists a clear need for indi-
cators of incipient congestive heart failure as well as of the
efficacy of therapeutic intervention. In this respect, haemo-
dynamic measurements are of limited help even under
exercise conditions. Neurohumoral factors are currently
thought to provide some early warning of imminent dis-
ease121, and they may indeed be used as a guide to assess
therapeutic effects. Plasma atrial natriuretic factor (ANF)
reflects early heart failure'4' and measurement of com-
ponents of the renin angiotensin system and of cate-
cholamines should be useful in evaluating the action of
ACE inhibitors. However, the question of the appropriate
dose of ACE inhibitor to be used remains unanswered
since hardly any dose-response relationships in congestive
heart failure have been reported'5'. For example, although
very low doses are commonly recommended for heart fail-
ure treatment, the recently reported beneficial clinical
effects were obtained with high doses.
In view of this, a placebo-controlled, double-blind paral-
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lei design 12-week study was undertaken to investigate the
dose-dependency of neurohumoral changes elicited by
quinapril in patients with moderate congestive heart fail-
ure under resting conditions and during exercise-induced
activation. Concomitant changes in clinical and haemo-
dynamic parameters were also recorded. The intention was
then to interrelate neurohumoral and haemodynamic
observations using adequate statistical analysis.
Methods
PATIENTS
We investigated 61 patients (53 males, eight females)
with congestive heart failure and a left ventricular ejection
fraction, as determined by biplane left ventricular angio-
graphy of <. 35% (range 15-35%, mean 30). They were 36
to 76 years old (mean 56). When entering the study, their
heart failure was evaluated according to the New York
Heart Association (NYHA) classification as stage II or III.
They had no severe concurrent organic illnesses and
patients with rapidly deteriorating chronic heart failure
were excluded. Further exclusion criteria were: significant
aortic or mitral stenosis, atrioventricular shunt, systolic
blood pressure below 100 rnmHg, recent myocardial
infarction within the 3 months preceding the study or prior
treatment with ACE inhibitors.
STUDY PROTOCOL
All patients received placebo twice daily during a 2-
week run-in period. Simultaneously other treatments were
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optimized: digitalis and/or limited amounts of diuretics
were allowed, and 15 patients with coronary artery disease
received salicylic acid together with diltiazem prophylacti-
cally. This concomitant treatment was then strictly main-
tained throughout the following 12-week study. On the
morning of the last day of the run-in period, patients
remained fasting but received the usual morning dose
of their concomitant treatment before right heart cath-
eterization was performed. Baseline haemodynamic
measurements and pulmonary artery blood samples for
neurohumoral measurements were obtained after a 60 min
rest in the supine position. Following ingestion of placebo,
patients remained in the supine position, and haemody-
namic and humoral measurements were repeated 2 and
3 h later (resting values). At 4 h post-dose and after repeat
resting assessment, patients started to exercise in the
supine position on a bicycle ergometer at 50 watts for 6
min. The moderate workload was chosen in order to create
a second stage for the evaluation of regulatory mecha-
nisms, but one which could still be met by all heart failure
patients. During the last minute of exercise, haemody-
namic and neurohumoral measurements were repeated
(exercise values). The participants were randomly assigned
to one of four treatments for the subsequent 12 weeks: fol-
lowing a double-blind protocol, quinapril at 2-5,5 or 10 mg
(low, intermediate or high dose) or placebo were adminis-
tered orally twice a day. The full intermediate and high
doses were administered on the second and third day of the
study respectively. On day 84 of the randomized treatment,
patients were reevaluated using the same protocol as at
the end of the placebo run-in period. The protocol was
approved by the Institutional Review Committees of the
hospitals involved. Goals and procedures of the trial
were explained to the patients and written consent was
obtained.
NEUROHUMORAL ASSESSMENT
All blood samples were collected on ice into pre-chilled
glass tubes containing heparin or ethylene diaminetetra
acetate (EDTA) as appropriate and additional metal-
loprotease and renin inhibitors for accurate angiotensin
measurements. Samples were immediately centrifuged at
4°C and duplicate plasma aliquots were snap frozen in
liquid nitrogen and stored at -80°C until analysed. Plasma
ACE activity was measured in vitro using two different
substrates, Phe-His-Leu (FHL, normal range 10-28
nmol.ml-'.min-')16'71 and Hippuryl-Gly-Gly (HGG,
normal range 70-140 nmol.ml.~1min~l)|iwl. ACE activity
was also estimated in vivo by the plasma angio-
tensin Il/angiotensin I (Ang l/Ang II) (normal range
0-4-2017101. Plasma renin activity (PRA) was determined
by antibody trapping of generated angiotensin I and subse-
quent radioimmunossay (PRA, normal range 0-2-20
ng.ml '.h"1)'11121. Ang I and II were quantitated by
radioimmunossay after solid-phase extraction on phenylsi-
lylsilica and subsequent HPLC-separation (Ang I, normal
range 0-8-12 fmol.ml"1; Ang II, normal range 0-8-7-6
fmol.mr1)1'3-141. Atrial natriuretic peptide (ANF, normal
range 4-34 fmol.mr1)1'51 was also extracted on phenylsilyl-
silica and measured radioimmunologically. Plasma norepi-
nephrine (normal range 50-400 pg.ml ') and epinephrine
(normal range: 50-150 pg.ml"1) were measured radioenzy-
matically using a modification of the method of Peuler and
Johnson!'5-16!.
HAEMODYNAMIC MEASUREMENTS
Right heart examinations were performed with Swan-
Ganz thermodilution catheters. Blood pressure was mea-
sured by sphygmomanometer. The following parameters
were determined: heart rate (HR), systolic (BP syst) and
diastolic blood pressure (BP diast), mean arterial pressure
(MAP), cardiac output, cardiac index (CI), pulmonary cap-
illary wedge pressure (PCWP), pulmonary artery systolic
(PAP syst), diastolic (PAP diast) and mean pressures (PAP
mean), right atrial pressure (RAP mean), total peripheral
resistance (TPR) and pulmonary vascular resistance
(PVR). At each time point, haemodynamic variables were
measured repeatedly to guarantee stability.
DATA ANALYSIS
Changes in neurohumoral variables from baseline to the
end of study were expressed as a percent of baseline
because the baseline values were very inhomogenous. In
contrast, absolute differences were used in the analysis of
haemodynamic variables because the haemodynamic base-
line values were more homogenous. Baseline was defined
as the examination one day before starting double-blind
therapy and changes from baseline were determined for
matching time points only. The mean from the 2- and 3-h
post-dose measurements was calculated and used to
enhance accuracy for post-dose resting values. All patients
who completed the study after 12 weeks of treatment
(n = 55) were evaluated for efficacy.
The statistical testing procedure was related to the two
objectives of the study, first to show superiority of quinapril
over placebo, second to investigate the dose-response rela-
tionship. For the first objective, a statistical testing hier-
archy was started comparing quinapril 20 mg with placebo.
Only if this showed significant results was the comparison
continued for quinapril 10 mg with placebo, and similarly
for quinapril 5 mg with placebo. For the second objective,
the testing hierarchy compared quinapril 20 mg with 5 mg,
and quinapril 10 mg with 5 mg and 20 mg. Both testing
hierarchies were based on the assumption that in the pres-
ence of a dose-response the dose effects are ordered by
dose.
The Wilcoxon rank-sum statistical test was used with a
significance level of 5%; no adjustments were made for
multiple testing.
Correlations between changes from baseline as regards
neurohumoral and haemodynamic variables were evalu-
ated by calculating the correlation coefficient of Spearman
and testing the difference of this coefficient from zero. All
analyses were done using SAS (Version 6-07).
Results
PATIENTS
Fifty-five patients completed the study while four men
(two on placebo, two on low dose quinapril) and two
women (one on low, one on high-dose quinapril) had to be
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withdrawn due to lack of compliance with the protocol
(four), progression of heart failure (one) and sudden death
due to arrhythmia (one). Five patients had serious adverse
events which could not be attributed to the ACE inhibitor
treatment. Of the low dose group, one patient had chest
pain with palpitations and one died. One patient in the high
dose group developed haemoptysis. TWo cases of diabetes
and cervical syndrome, one with accompanying thoracic
pain, were observed in the placebo group. Other untoward
events without any dose-relationship were: hypotension
(seven), syncope (three), cough (two), rash or photosensi-
tive reaction (two), pruritus (one), nausea (two), diarrhea
(one) and muscle cramp (one). There were no major
differences in baseline haemodynamic or neurohumoral
characteristics among the four treatment groups at
randomization, except for higher in vitro plasma ACE
activities in patients receiving placebo during the 12-week
intervention phase (Table 1). There was no apparent
reason for the mismatch of the latter group. In none of the
treatment groups were baseline PRA or angiotensins
increased above normal; they were low in the 10 and 20 mg
groups where diuretic treatment was less frequent.
NEUROHUMORAL CHANGES
Table 2 summarizes the pooled plasma neurohumoral
results of all patients at rest (means of 2 and 3 h post-dose)
and after exercise at the end of the placebo run-in period.
All parameters were stable during the pre-exercise phase
(not shown) and median as well as mean values were
within the normal range except for the clearly increased
ANF concentrations. Baseline norepinephrine levels at
rest were in 30/55 patients below 300 pg.ml"1, in 13/55
above 400 pg.ml"1 and in 6/55 above 600 pg.ml"'. Exercise
stimulated all humoral parameters including ACE activi-
ties in vitro and in vivo (Fig. 1).
Treatment with the low, intermediate and high doses of
quinapril changed all variables in the rerun angiotensin
system at trough (pre-dose, not shown), resting at peak
(Table 3) and during exercise (Table 4). Only the reduction
in Ang II with the low and intermediate doses was not sig-
nificant. Median percent decreases in Ang II levels fol-
lowed the dose increases both at rest and after exercise
when they were reduced by 6, 42, 59 and 68% (P < 001)
for placebo, low, intermediate and high doses respectively
(Fig. 2). PRA and Ang I concentrations sharply increased
with all three quinapril doses at rest as well as during exer-
cise (P < 0-01), but no dose-dependency was found. The
dose-relationship for the reduction of ACE activity
by quinapril is also depicted in Fig. 2. ACE activity
was strongly inhibited in vitro (HGG, FHL) and in vivo
Table 1 Patient characteristics
Variable
Sex(n)
Men
Women
Age (years)
median
(range)
Body surface area (m2)
median
(range)
Duration of CHF (years)
median
(range)
Left ventricular end-diastolic volume index (ml.nr2)
Mean
(SEM)
Left ventricular end-diastolic pressure (mmHg)
Mean
(SEM)
Left ventricular ejection fraction (%)
Mean
(SEM)
Aetiology* CHF (n)
Ischaemic
Dilatative
Hypertension
Other
Concurrent CHF treatment (n)
Digitalis
Diuretics
Placebo
14
1
55
(40-67)
2-0
(1-7-2-2)
0-5
(02-3-7)
142
(11)
17-5
(1-6)
31-2
(11)
12
4
2
1
8
12
Quinapril treatment group
Low dose
14
2
65
(42-76)
1-9
(1-5-2-0)
0-5
(CM)
158
(13)
15-6
(1-5)
28-4
(1-4)
10
6
1
0
10
14
Medium dose
13
2
54
(39-75)
1-9
(1-5-2-1)
20
(0-1-11)
139
(6)
17-0
(1-9)
31-0
(0-9)
12
4
2
1
4
6
High dose
12
3
54
(36-60)
2-0
(1-3-2-3)
1-2
(0-2-16) -
162
(11)
17-7
(1-9)
27-5
(1-9)
9
6
2
0
6
7
1
 More than one aetiology per patient was possible; CHF = congestive heart failure.
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Table 2 Neurohormonal and haemodynamic data al baseline
Variable
Neurohormones
PRA(ng.ml- ' . rr ' )
Ang I (fmol.ml-1)
Ang II (fmol.ml-1)
Ang II/Ang I
ACE (HGG) (nmol.ml-'.min-1)
ACE (FHL) (nmol.ml-'.min-1)
ANF (fmol.ml-1)
Norepinephrine (pg.mr1)
Epinephrine (pg.mr1)
Haemodynamics
Heart rate (min"')
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Mean blood pressure (mmHg)
PCWP (mmHg)
PAP systolic (mmHg)
PAP diastolic (mmHg)
PAP mean (mmHg)
RAP mean (mmHg)
Cardiac index (l.min-'.m"2)
n
54
53
54
53
55
55
55
55
55
55
54
54
54
53
55
55
55
51
55
Mean
102
7-9
3-6
0-57
95-6
195
92
318
73
73-4
125-3
80-4
95-4
104
31-0
13-5
19-7
4-2
2-7
Resting
(SEM)
(0-18)
(1-4)
(0-5)
(0-05)
(34)
(0 8)
(10)
(28)
(13)
(19)
(24)
(1-3)
(1-6)
(0-6)
(1-6)
(0-8)
(1-1)
(0-29)
(0-07)
Median
0-56
5-3
2-3
0-51
89
185
68
247
48
74
122-5
80
94-2
10
28
12
18
4-5
2-7
n
53
52
53
52
53
53
53
53
53
55
49
49
49
48
55
55
55
51
53
Mean
2-00
13-5
9-8
0-85
97-8
19-7
183
905
153
109-5
152-2
911
111-5
251
581
29-3
39-8
7-2
4-3
Exercise
(SEM)
(046)
(2-8)
(2-1)
(0-10)
(3-4)
(0-8)
(19)
(88)
(30)
(2-2)
(34)
(1-8)
(21)
(1-5)
(24)
(14)
(1-8)
(0-59)
(014)
Median
0-70
5-3
4-4
0-75
93
18-6
148
762
104
112
150
90
110
23
55
28
39
6
4-3
PRA = plasma renin activity; HGG = hippuryl-glycyl-glycine; FHL = phenyl-histidyl-leucine; ANF = atnal natriuretic factor;
PCWP = pulmonary capillary wedge pressure; PAP = pulmonary artery pressure; RAP = right atrial pressure.
(Ang II/Ang I) with all three doses of quinapril (P < 001,
Tables 3 and 4). In contrast, chronic ACE inhibition did not
affect plasma ANF, epinephrine or norepinephrine.
HAEMODYNAMIC RESPONSES
Table 2 shows pooled resting and exercise haemody-
namics for all patients at the end of the placebo run-in
period. As expected, during exercise, heart rate, blood
pressure, right atrial pressure, pulmonary capillary wedge
pressure as well as cardiac index increased, while periph-
eral vascular resistance fell.
Chronic quinapril treatment induced only small haemo-
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Figure 1 Exercise increased plasma ACE activity. Measured with three independent
methods using hippuryl-glycyl-glycine (HGG) or phenyl-histidyl-leucine (FHL) for estima-
tion in vitro and the plasma Ang II/Ang I ratio in vivo, median ACE activity increased with
exercise consistently. This effect was entirely abolished after chronic treatment with quinapril
while preserved under placebo. "I"" P < 005/001.
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Table 3 Resting neurohumoral resultst
Neurohumoral parameter
Plasma renin activity (ng.ml"'.h"!)
BL
At*
Ang I (fmol.ml-1)
BL
A
Ang II (fmol.ml-1)
BL
A
Ang 11/Ang I
BL
A
ACE activity HGG (nmol.mr'.mirr1)
BL
A
ACE activity FHL (nmol.ml~1.mirrl)
BL
A
Atrial natriuretic factor (fmol.ml"1)
BL
A
Norepinephrine (pg.ml"1)
BL
A
Epinephrine (pg.ml"1)
BL
A
Placebo
081
-17(13)
6-2
-23(12)
3-1
-42-6(13)
O48
-209(12)
106-0
1-7(13)
24-6
3-8(13)
51
-13(13)
238
13(13)
49
-25(13)
Quinapril
5mg
1-09
154**(13)
7-4
355**(13)
3-0
-59-5(13)
036
-92-8**(13)
84-5
-98-l**(13)
17-2
-911**(13)
94
18(13)
344
2(13)
55
-16(13)
Quinapril
10 mg
0-25
213"(15)
2-5
444"(15)
1-9
-63-6(15)
054
-91-7**(15)
85-5
-96-9"(15)
17-2
-92-8**(15)
55
-12(15)
212
11(15)
38
-4(15)
Quinapril
20 mg
0-50
224**(13)
4-6
289**(13)
2-3
-64-7**(13)
042
-92-5**(13)
92-5
-99-3"(14)
18-7
-95-4**tt§§(14)
54
-14(14)
325
-10(14)
46
-21(14)
*• P £, O01 for quinapril 20,10 and 5 mg vs placebo,
ft P :£ O01 for quinapril 20,10 vs 5 mg,
§§ P s 0-01 for quinapril 20 vs 10 mg,
based on Wilcoxon rank-sum test.
t Mean of 2 and 3 h post-dose measurements.
tt Median of the percent changes from baseline resting values.
BL = median baseline; A = median % change (n); for other explanations of abbreviations see Table 2.
dynamic changes, with very similar trough and peak effects
on resting haemodynamics. Table 5 shows resting baseline
pre-treatment values and the corresponding mean of
absolute changes at 2-3 h after the last quinapril or placebo
dose. The decrease in pulmonary artery systolic pressure
was significant for the intermediate and high doses
(P < 0-01). The latter finding was confirmed by similar
decreases in the corresponding wedge pressures (P < 0-05)
and by significant decreases in systolic pulmonary artery
pressures at trough (P < 005 for intermediate, P < 0-01 for
high doses). During exercise, the haemodynamic changes
induced by chronic quinapril treatment tended to be
greater than those observed at rest, but they did not reach
statistical significance due to larger scattering of the vari-
ables (Table 6).
CORRELATIONS BETWEEN NEUROHUMORAL AND
HAEMODYNAMIC CHANGES
Spearman correlation coefficients for corresponding bio-
chemical and haemodynamic modifications induced by the
12-week treatment with placebo and the three quinapril
doses are listed in Table 7(a) for resting and in Table 7(b)
for exercise values. There were several trends pointing to a
relationship between neurohumoral and haemodynamic
changes. A positive correlation was found between
changes in plasma ANF and in both PAP syst (R = 0-44, P
< 0-01) and PAP diast (R = 0-49, P < 0-01) at rest. The lat-
ter correlation remained significant during exercise
(R = 0-30, P < 005). The significance of the correlation
between changes in ACE activity and PAP syst at rest
(FHL, R = 0-28, P < 005) was confirmed by both methods
of ACE measurement when trough values were compared:
FHL, R = 0-32, P < 0-05 and HGG, R = 0-36,
P < 0-01 (data not shown in Table 7(a). In contrast,
changes in PAP syst at rest were inversely correlated with
PRA changes (R-0-43, P < 0-01). Positive correlations
were also observed between changes in ACE activity and
mean arterial pressure during exercise (FHL, R = 0-41,
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Table 4 Exercise neurohumoral resultsX
Neurohumoral parameter
Plasma renin activity (ng.ml~'.h~')
BL
Angl(fmol.ml-')
BL
A
Angll (fmol.mr1)
BL
A
Ang Il/Ang 1
BL
A
ACE activity HGG (nmol.ml~1.mirr1)
BL
A
ACE activity FHL (nmol.ml~l.tnin"1)
BL
A
Atrial natriuretic factor (fmol.mr1)
BL
A
Norepinephrine (pg.ml"1)
BL
A
Epinephrine (pg.ml"1)
BL
A
Placebo
1-03
-22(12)
7-8
-18(11)
4-9
-5-8(12)
077
-4-3(11)
108-0
-4-6(12)
25-2
3-3(12)
76
-25(12)
767
1(12)
108
-26(12)
Quinapril
5 mg
2-40
194**(13)
13-0
641**(13)
8-4
-41-9(13)
0-70
-9O7**(13)
900
-97-7**(13)
17-5
-89-5**(13)
175
11(13)
787
-2(13)
117
21(13)
Quinapril
10 mg
0-33
302**(15)
4-0
275**(15)
2-8
-58-8(15)
0-98
-92-0**(15)
91 0
-98-0**(15)
16-9
-92-7**(15)
139
-31(15)
654
-22(15)
98
7(15)
Quinapril
20 mg
0-67
205**(13)
5-1
311«(13)
2-9
-67-9**(13)
0-69
-92-9**(13)
93-0
-99-9**t§§(13)
18-6
-94-0**tt§(13)
131
-5(13)
762
-8(13)
80
-23(13)
" P s 001 for quinapril 20, 10 and 5 mg vs placebo,
t / t t P s 0-05/O01 for quinapril 20, 10 vs 5 mg,
§/§§ P =s 005/O01 for quinapril 20 vs 10 mg,
based on Wilcoxon rank-sum test.
t 6 min exercise at 50 watts, 4 h post-dose.
tt Median of the percent changes from baseline exercise values.
BL = median baseline; A = median % change (n).
P < 001 and HGG, R = 0-37, P < 005) and at rest (HGG,
R = 0-27, P < 005). The latter finding was also confirmed
by the FHL method at trough with R = 0-30, P < 0-05.
At rest, changes in cardiac index were correlated with
those of ACE activity in vivo as measured by the plasma
Ang II/Ang I ratio (R = 0-28, P < 0-05) and this was again
corroborated by an even better correlation at trough
(R = 0-36, P < 001, not shown). During exercise, the
quinapril effect on norepinephrine concentrations paral-
leled changes in mean arterial pressure (R = 0-30,
P < 005) and in PAP diast (R = 0-44, P < 001).
Discussion
This study was designed to assess dose-dependent effects
of ACE inhibition by quinapril in patients with moderate
congestive heart failure. At the outset, it seemed unlikely
that dose-dependent haemodynamic effects could be
demonstrated. However, in accordance with the wide-
spread opinion that neurohumoral variables are more sen-
sitive and therefore better at reflecting dose-dependency of
drug-induced effects, special emphasis was given to the
accuracy of the methods used to measure these parameters.
In the carefully characterized patients with moderate
congestive heart failure, dose-dependent reduction of
plasma converting enzyme activity could be demonstrated
using two different methods. The effect was observed under
resting as well as under exercise conditions. Interestingly,
Riegger has discussed increases in exercise time as a sign
for dose-dependency in his heart failure patients assuming
a no difference in ACE inhibition131.
Varying degrees of ACE inhibition at the top end of the
dose-response relationship may be particularly important as
ACE is present in great abundance and only a few percent of
remaining ACE activity, i.e. the difference between 90 and
93% inhibition, may produce distinctly different amounts of
Ang II. Thus, these small modulations of plasma ACE activ-
ity should, if meaningful, relate to changes in plasma Ang II
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Figure 2 Dose-dependency of ACE inhibition after quinapril (day 84 vs base-
line day-1). Box plots show median, interquartile range (25% to 75%) and
extremes. Dose-dependency is significant for ACE activity (FHL, phenyl-his-
tidyl-leucine) and suggested for plasma Ang II concentration. Depicted are
values during exercise. ** P < O01.
levels. In fact, the reduction in plasma Ang II reached statis-
tical significance only with the high dose of quinapril (Table
3); a clear trend towards dose-dependency of this decrease
was observed during exercise (Fig. 2). At rest, the levels of
plasma Ang II after 12 weeks treatment were at 1-8, 1-2, 0-7
and 0-8 fmol.ml"1 respectively with increasing doses of
quinapril. At exercise, the same values for plasma Ang II
were markedly higher in the placebo and 5 mg groups, at 4-6
and 4-9 fmol.ml1, while in the 10 and 20 mg groups they were
reduced to 1-2 and 0-9 fmol.ml"1 respectively. Since only a
low level of exercise was used, these dose-dependent reduc-
tions in plasma Ang II reflect treatment effects during daily
life much better than resting values. Dose-dependent Ang II
concentrations at moderate exercise, in turn, correlated with
some haemodynamic results and thus translated into clinical
effects. The neurohumoral data obtained, not only from rest-
ing but even more so those measured during exercise condi-
tions, are clearly complementary to the recently published
neurohumoral data from the CONSENSUS"7' and SOLVD'2'
trials.
In the present study, normal median plasma renin and
Ang II levels were found in patients with moderate con-
gestive heart failure and left ventricular ejection fractions
below <, 35%, even though 36 out of these 55 patients
were on diuretic treatment. Only seven patients had a
moderately stimulated renin angiotensin system (RAS).
Consequently, a major result was the relative lack of acti-
vation of the plasma RAS in moderate heart failure. The
plasma RAS did not seem to provide a sensitive parameter
to reflect mild to moderate ventricular dysfunction and
therefore could not be used as an indicator for specific
therapy. Notwithstanding this, during therapy, components
of the plasma RAS reasonably correlated with haemody-
namic parameters at rest and at exercise (see Table 7).
Thus, the observed small changes in the plasma RAS may
have mediated dose-dependent therapeutic effects
Comparable data have been obtained for plasma norep-
inephrine. Despite established congestive heart failure,
only 24% of our patients had clearly raised norepinephrine
levels above 400 pg.ml"' when entering the trial. Thus,
plasma norepinephrine levels, like plasma RAS activity,
cannot be used as guidelines for therapy. Treatment-
induced changes in norepinephrine were, however,
associated with haemodynamic changes at exercise. Both
exercise mean arterial pressure and diastolic pulmonary
artery pressure changed over the 12-week treatment
period together with plasma norepinephrine concentra-
tions. The difference between the pre- and post-treatment
changes in cardiac index and diastolic pulmonary artery
pressure induced by exercise were well correlated with the
corresponding changes in norepinephrine responses to
exercise. We found no effect of the quinapril treatment on
baseline norepinephrine plasma concentrations in our
patients. This is in agreement with the findings of
Goldsmith and his co-workers, who demonstrated an
absent norepinephrine response to both enalaprilat and
Ang II infusion in patients with moderate heart failure1'81.
Tissue catecholamines reflect cardiac dysfunction better
than plasma catecholamines, so it may be that tissue Ang II
is also a better indicator of disease than plasma Ang II or
ACE activity. This hypothesis remains to be substantiated
with adequate methodology.
An increase in plasma ACE activity during a moderate
workload was observed using three different, independent
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Table 5 Resting haemodynamic results%
Haemodynamic parameter
Heart rate (beatsmin"1)
BL
AM
Mean arterial pressure (mmHg)
BL
A
Cardiac index (l.min~'.m~2)
BL
A
Pulmonary artery systolic pressure (mmHg)
BL
A
Pulmonary artery diastolic pressure (mmHg)
BL
A
Right atrial pressure (mmHg)
BL
A
Placebo
73-5
3-8(13)
97-6
2-9(13)
2-7
0-2(13)
31-6
5-8(13)
13-6
1-8(13)
3-7
07(12)
Quinapril
5mg
76-5
-3-5(13)
96-2
-2-2(13)
2-7
-0-0(13)
30-3
1-7(13)
12-8
0-8(13)
3-4
0-2(12)
Quinapril
10 mg
69-3
-1-6(15)
951
0-5(14)
2-9
0-1(15)
31-0
-2-3*'(15)
14-0
-2-0(15)
4-1
-0-8(14)
Quinapril
20 mg
74-9
-1-9(14)
92-9
-0-5(14)
2-7
0-2(14)
30-9
-2-7«(14)
13-6
-0-5(14)
5-4
-0-9(13)
•* P =s 001 for quinapril 20,10 mg vsplacebo,
based on Wilcoxon rank-sum test.
% Mean of 2 and 3 h post-dose treatments,
t t Mean changes from baseline resting values.
BL = median baseline; A = mean change (n).
Table 6 Exercise haemodynamic resultst
Haemodynamic parameter
Heart rate (beats.min~')
BL
At*
Mean arterial pressure (mmHg)
BL
A
Cardiac index (l.min~'.m~2)
BL
A
Pulmonary artery systolic pressure (mmHg)
BL
A
Pulmonary artery diastolic pressure (mmHg)
BL
A
Right atrial pressure (mmHg)
BL
A
Placebo
106-3
0-8(13)
111-8
3-3(10)
4-3
0-3(13)
58-8
-3-5(13)
28-7
-3-7(13)
6-5
0-8(12)
Quinapril
5mg
106-8
5-3(13)
105-2
2-8(10)
4-4
-0-1(12)
55-8
3-4(13)
26-2
1-2(13)
7-2
1-0(12)
Quinapril
10 mg
111-5
-1-7(15)
114-8
-2-6(15)
4-6
0-2(15)
57-7
-4-4(15)
31-2
-4-5(15)
6-9
-0-3(14)
Quinapril
20 mg
112-9
0-4(14)
112-3
-5-5(14)
41
1-0(13)
60-2
-7-8(14)
30-8
-4-1(14)
80
-0-1(13)
t 6 min exercise at 50 watts, 4 h post-dose.
t t Mean changes from baseline exercise values.
BL = mean baseline; A = mean change (n).
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Table 7(a) Spearman correlation coefficients for changes induced by 12-week quinapril
treatment; resting conditions
Neurohormonal
parameter
Plasma renin activity
Angll
Ang Il/Ang I
ACE activity, Hip-Gly-Gly
ACE activity, Phe-His-Leu
Atrial natriuretic factor
Norepinephrine
MAP
-0-24
-0-09
0-02
0-27*
0-21
0-12
0-18
Haemodynamic parameter
PAP systolic
- 0 - 4 3 "
-0-04
0-24
0-26
0-28*
0-44"
-0-07
PAP diastolic
-0-26
- 0 1 6
0-12
0-18
0-19
0-49"
0-02
*/•* P < 0-05/0-01.
Table 7(b) Spearman correlation coefficients for changes induced by 12-week quinapril
treatment; exercise conditions
Neurohormonal
parameter
Plasma renin activity
Ang II
Ang 11/Ang I
ACE activity, Hip-Gly-Gly
ACE activity, Phe-His-Leu
Atrial natriuretic factor
Norepinephrine
MAP
- 0 1 9
- 0 1 4
019
0-37*
0-41**
-0-05
0-30*
Haemodynamic parameter
PAP systolic
-0-18
-O06
027
0-19
0-22
0-26
0-25
PAP diastolic
-0-12
-0-28*
0-28*
Oil
016
0-30*
044**
•/•* /)<0-05/O01.
For explanation of abbreviations see Table 2.
methods. After the treatment period, patients on placebo
still had increased ACE activity during exercise whereas
quinapril treatment abolished the effect (Fig. 1). It is con-
ceivable that changes in blood pressure and/or flow in the
lungs combined with an enhanced shear stress on the
endothelial cells account for this increase in ACE activity.
The good correlation between plasma ANF and pul-
monary artery pressures is not a surprise and once more
emphasizes that ANF is an excellent indicator of the pres-
sure load in the heart. Indeed, more than 80% of all our
patients with only moderate congestive heart failure exhib-
ited an elevated ANF level despite the additional fact that
a majority of them were on diuretics, which are known to
reduce ANF levels under physiological conditions.
In conclusion, in these patients with moderate conges-
tive heart failure the plasma RAS was not activated. The
effect of 3-month ACE inhibition on circulating humoral
components was smaller than anticipated but more clearly
dose-dependent than the haemodynamic responses. Never-
theless, these small modifications of neurohumoral vari-
ables were reasonably related to haemodynamic changes
and hence could account for therapeutic effects even in
patients with moderate heart failure. The most favourable
trends and significant changes were observed after the
highest dose of quinapril, which resulted in the greatest
degree of ACE inhibition and the lowest plasma Ang II
levels at moderate exercise. These data suggest that for
long-term treatment ACE inhibitors should not be admin-
istered at a reduced dose. This is in keeping with the recent
SOLVD and SAVE data which were also obtained with
higher doses than those commonly recommended for initi-
ation of therapy.
The study group consisted of the following physicians: Berlin: E.
Fleck, V. Regitz, B. Struck, F. Wagner, Diisseldorf: H. P.
Schultheiss, B. Witzenbichler, Munich: D. Antoni, W. Delius, H. J.
Krieg; Lausanne: H. R. Brunner, J. Nussberger. The study group
coordination and statistical evaluation was done by H. Bahrmann
and J. Lilienthal, Parke Davis Co., Freiburg.
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